Abstract
New strategies for myocardial protection and regeneration after myocardial infarction are urgently needed to counter the heart failure pandemic. To address this unmet medical need, Kaur and colleagues (in this issue of Molecular Therapy)1 have identified in a preclinical proof-of-concept study a cocktail of modified RNA (modRNA) to endow stromal cells with angiogenic growth factor releasing activity (Figure 1). Sustained angiogenic programming was realized by lipid-nanoparticle (LNP) delivery, using formulations that have been employed safely and efficaciously in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
